Showing results (341-350 of 374) with videos related to

Sort By:
Pageof 38
The Lancet. Oncology|May 31, 2026
Cancer workforce-a global crisis: a Lancet Oncology CommissionHedvig Hricak, Zachary J Ward, Fabio Ynoe Moraes, et al.
The Lancet. Oncology|April 16, 2014
The growing burden of cancer in India: epidemiology and social contextMohandas K Mallath, David G Taylor, Rajendra A Badwe, et al.
BMJ Open|November 18, 2020
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort studyAlvina G Lai, Laura Pasea, Amitava Banerjee, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
Nature Cancer|January 3, 2025
The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysisRicha Shah, Nader Mounir Hanna, Ching Ee Loo, et al.
Frontiers in Veterinary Science|November 29, 2023
Incorporating biodiversity responses to land use change scenarios for preventing emerging zoonotic diseases in areas of unknown host-pathogen interactionsFabio de Oliveira Roque, Beatriz Bellón, Angélica Guerra, et al.
Nature Medicine|April 20, 2022
Priorities for cancer research in low- and middle-income countries: a global perspectiveC S Pramesh, Rajendra A Badwe, Nirmala Bhoo-Pathy, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer|January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-GuerinRafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
Pageof 38